Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H21FO5S |
Molecular Weight | 404.452 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC=C(F)C(CC3=CC4=C(S3)C=CC=C4)=C2
InChI
InChIKey=AHFWIQIYAXSLBA-RQXATKFSSA-N
InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
Molecular Formula | C21H21FO5S |
Molecular Weight | 404.452 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ipragliflozin is an orally active, next-generation sodium glucose transporter-2 (SGLT2) inhibitor that has been developed by Astellas Pharma and Kotobuki. SGLTs are membrane proteins exist on the cell surface and transfer glucose into cells. SGLT2 is one subtype of SGLTs that plays a key role in the reuptake of glucose in the the proximal tubule of the kidneys. By selectively inhibiting SGLT2, Ipragliflozin suppresses the reuptake of glucose and reduces blood glucose levels. Ipragliflozin received marketing approval for the indication of type 2 diabetes under the brand name Suglat® Tablets in January 2014 and has been on the market since April 2014.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22507206 |
7.38 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. | 2011 Dec |
|
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. | 2011 Dec 1 |
|
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. | 2012 |
|
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. | 2012 Apr |
|
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. | 2012 Aug |
|
Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. | 2012 May 15 |
|
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. | 2012 Oct |
|
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. | 2013 May |
|
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. | 2013 May |
|
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. | 2013 May-Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.pmda.go.jp/files/000206796.pdf
The usual adult dosage is 50 mg of ipragliflozin orally administered once daily before or after breakfast. The dose may be increased up to 100 mg once daily with careful monitoring of the patient’s clinical course in the case of inadequate efficacy.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:56:56 GMT 2023
by
admin
on
Sat Dec 16 17:56:56 GMT 2023
|
Record UNII |
3N2N8OOR7X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A10BK05
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
761423-87-4
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
C572941
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
10453870
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
DB11698
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
C166685
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
DTXSID701032738
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
100000128632
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
Ipragliflozin
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
4890
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
SUB35918
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
3N2N8OOR7X
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
9258
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY | |||
|
m11865
Created by
admin on Sat Dec 16 17:56:57 GMT 2023 , Edited by admin on Sat Dec 16 17:56:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |